KRAS mutations were detected in 44 of 79 (56%) plasma samples at baseline, in 42 of 62 (63%) samples from patients with metastatic disease, and in two of 12 (17%) samples from patients with locally advanced disease (P = 0.004). This evidence concerns the gene KRAS and metastatic neoplasm.